Quoin Pharmaceuticals Received Written Notice From Nasdaq Regarding Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals has received a written notice from Nasdaq concerning its failure to meet the minimum bid price requirement, according to an SEC filing.

May 03, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Quoin Pharmaceuticals has been notified by Nasdaq for not meeting the minimum bid price requirement.
Receiving a notice from Nasdaq about failing to meet the minimum bid price requirement is a negative signal to the market. It indicates that the stock price has been below the Nasdaq's minimum threshold, which could lead to potential delisting if not corrected. This news is likely to negatively impact investor confidence and could lead to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100